In this study, multiple lines of evidence support that TIAM1 is a critical driver of prostatic budding and branching in BPH and suggest that targeting the TIAM1/RAC1 axis may be a potentially effective treatment strategy. The gene discussed is RAC1; the disease is benign prostatic hyperplasia.